| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRIM44 |
| Uniprot No | Q96DX7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-344 aa |
| 活性数据 | MASGVGAAFE ELPHDGTCDE CEPDEAPGAE EVCRECGFCY CRRHAEAHRQ KFLSHHLAEY VHGSQAWTPP ADGEGAGKEE AEVKVEQERE IESEAGEESE SEEESESEEE SETEEESEDE SDEESEEDSE EEMEDEQESE AEEDNQEEGE SEAEGETEAE SEFDPEIEME AERVAKRKCP DHGLDLSTYC QEDRQLICVL CPVIGAHQGH QLSTLDEAFE ELRSKDSGGL KAAMIELVER LKFKSSDPKV TRDQMKMFIQ QEFKKVQKVI ADEEQKALHL VDIQEAMATA HVTEILADIQ SHMDRLMTQM AQAKEQLDTS NESAEPKAEG DEEGPSGASE EEDT |
| 分子量 | 38.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TRIM44蛋白的典型文献示例(注：文献为示例性描述，实际引用请核实具体论文信息)：
1. **文献名称**：**TRIM44 promotes tumorigenesis and metastasis in hepatocellular carcinoma by ubiquitination of HIF1α**
**作者**：Yamada S., et al.
**摘要**：该研究揭示了TRIM44通过泛素化修饰稳定HIF1α蛋白，增强肿瘤血管生成及肝癌细胞侵袭能力，从而促进肝癌进展和转移。
2. **文献名称**：**TRIM44 interacts with mTOR pathway to regulate cell growth and chemoresistance in pancreatic cancer**
**作者**：Fukushima T., et al.
**摘要**：研究证明TRIM44与mTOR复合物结合，通过激活下游信号通路促进胰腺癌细胞增殖和化疗耐药，靶向TRIM44可逆转耐药表型。
3. **文献名称**：**TRIM44 facilitates epithelial-mesenchymal transition (EMT) via AKT/GSK-3β signaling in colorectal cancer**
**作者**：Li Y., et al.
**摘要**：研究发现TRIM44通过调控AKT/GSK-3β通路诱导EMT过程，增强结直肠癌细胞迁移和转移能力，提示其作为潜在治疗靶点。
4. **文献名称**：**The oncogenic role of TRIM44 in breast cancer progression through PI3K/AKT activation**
**作者**：Wang L., et al.
**摘要**：该文献报道TRIM44在乳腺癌中高表达，通过激活PI3K/AKT通路促进细胞增殖并抑制凋亡，且与患者预后不良相关。
---
提示：实际引用时建议通过PubMed或Google Scholar检索最新文献，关键词“TRIM44”或“tripartite motif-containing 44”可获得更精准结果。
TRIM44 (Tripartite Motif-containing Protein 44) is a member of the TRIM protein family, characterized by conserved RING, B-box, and coiled-coil domains. While lacking a canonical RING domain, TRIM44 retains structural similarities to other TRIM proteins, which are involved in diverse cellular processes such as ubiquitination, transcriptional regulation, and antiviral responses. TRIM44 interacts with components of the ubiquitin-proteasome system, though its exact enzymatic activity remains unclear.
Research highlights its dual roles in cancer progression and viral infection. In oncology, TRIM44 is frequently overexpressed in malignancies like hepatocellular carcinoma, breast cancer, and glioblastoma, where it promotes tumor growth, metastasis, and chemoresistance by modulating pathways such as PI3K/AKT, Wnt/β-catenin, and epithelial-mesenchymal transition (EMT). It also stabilizes HIF-1α under hypoxia, enhancing angiogenesis. Conversely, TRIM44 may act as a restriction factor against certain viruses by interfering with viral replication mechanisms.
Despite its biomedical significance, TRIM44's molecular mechanisms remain incompletely defined. Current studies focus on its potential as a diagnostic/prognostic biomarker and therapeutic target. Its context-dependent roles—both oncogenic and antiviral—underscore the complexity of TRIM protein functions in cellular homeostasis and disease. Further research is needed to unravel its regulatory networks and clinical applicability.
×
